Trastuzumab: observed

142 studies: patients on it are followed, or it is given outside a trial. Page 1 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingNCT07856225Report a problem
• Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaRecruitingNCT07856212Report a problem
• GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingRecruitingNCT07583485Report a problem
• Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingNCT07545486Report a problem
• A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT07540520Report a problem
• Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNot yet recruitingNCT07470203Report a problem
• Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast CancerRecruitingNCT07166185Report a problem
• Impact of CES1 Genotype on Capecitabine Exposure in Cancer PatientsRecruitingNCT07114627Report a problem
• Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
• Emotional Distress in Patients With Metastatic Breast Cancer in First Line of TherapyRecruitingNCT06994377Report a problem
• Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABCRecruitingNCT06754059Report a problem
• Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast CancerRecruitingNCT06722612Report a problem
• Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive PatientsRecruitingNCT06722599Report a problem
• Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target TherapyRecruitingNCT06711068Report a problem
• Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast CancerRecruitingNCT06711055Report a problem
• De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive PatientsRecruitingNCT06700369Report a problem
• Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant TherapyRecruitingNCT06693037Report a problem
• Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast CancerNot yet recruitingNCT06537674Report a problem
• Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics IntegrationRecruitingNCT06396143Report a problem
• Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer ChemotherapyRecruitingNCT06282796Report a problem
• The Effects of HER2 Receptor Signaling on Human Brown Fat ActivityRecruitingNCT06222957Report a problem
• Detection and Prevention of Cancer-Related Cardiovascular Toxicity RegistryRecruitingNCT06086132Report a problem
• Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer PatientsRecruitingNCT05981326Not applicableReport a problem
• Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast CancerRecruitingNCT05912062Report a problem
• Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer PatientsRecruitingNCT05680194Report a problem
• Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective StudyRecruitingNCT05444647Report a problem
• Neoadjuvant Treatment of Breast CancerNot yet recruitingNCT05131893Report a problem
• Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical StudyNot yet recruitingNCT04831528Report a problem
• ctDNA Screening in Advanced HER2 Positive Gastric CancerRecruitingNCT04520295Report a problem
• Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast CancerRecruitingNCT04281641Not applicableReport a problem
• Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer PatientsRecruitingNCT02772367Report a problem
• Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast CancerRecruitingNCT02541435Report a problem
• Cardiotoxicity of Cancer Therapy (CCT)Enrolling by invitationNCT01173341Report a problem
• Safety and Efficacy of Trastuzumab BSCompletedNCT04181333Results postedReport a problem
• A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer PatientsActive, not recruitingNCT03983382Results postedReport a problem
• A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BCTerminatedNCT02771795Results postedReport a problem
• Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) CarcinomaCompletedNCT02731313Results postedReport a problem
• An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)CompletedNCT02658461Results postedReport a problem
• An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 YearsCompletedNCT01480674Results postedReport a problem
• An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)CompletedNCT01332981Results postedReport a problem
• An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT01187381Results postedReport a problem
• First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast CancerCompletedNCT07829900Report a problem
• Oncology Treatment Related Ocular Surface ChangesCompletedNCT07666724Report a problem
• Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast CancerCompletedNCT07416409Report a problem
• Extracellular Fluid Changes During Neoadjuvant ChemotherapyCompletedNCT07315880Report a problem
• Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric CancerCompletedNCT07009600Report a problem
• Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)CompletedNCT06996548Report a problem
• Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.CompletedNCT06961331Report a problem
• An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID StudyCompletedNCT06835348Report a problem
• Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentActive, not recruitingNCT06663787Report a problem
• Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: Comparison of Paclitaxel vs Paclitaxel + Trastuzumab vs Paclitaxel + Carboplatine: the PROTECT-06 Bis StudyTerminatedNCT06536556Report a problem
• RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal AntibodyActive, not recruitingNCT06481553Report a problem
• Young Patients With Early Breast CancerActive, not recruitingNCT06027541Report a problem
• AryoTrust® (Trastuzumab) Safety StudyCompletedNCT06021379Report a problem
• Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic ReviewCompletedNCT05931042Report a problem
• Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer PatientsCompletedNCT05839288Report a problem
• Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast CancerTerminatedNCT05803889Report a problem
• Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus TrastuzumabCompletedNCT05572645Report a problem
• KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingNCT05525858Report a problem
• Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletedNCT05253911Report a problem
• Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With TrastuzumabStatus unknownNCT05188495Report a problem
• a Prospective Registration Study for Patients With Advanced Refractory Solid TumorsStatus unknownNCT05177666Report a problem
• Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast CancerActive, not recruitingNCT05078190Report a problem
• A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast CancerStatus unknownNCT05030519Report a problem
• Investigating the Long-term Cardiac Sequelae of Trastuzumab TherapyStatus unknownNCT05019365Report a problem
• Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer PatientsStatus unknownNCT04962425Report a problem
• Evaluation of Heart Function in Breast Cancer Patients Using TrastuzumabStatus unknownNCT04961307Report a problem
• Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective PatientsCompletedNCT04920747Report a problem
• Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 TreatmentStatus unknownNCT04769050Report a problem
• The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab TherapyStatus unknownNCT04765124Report a problem
• Efficacy and Safety of Eribulin in the Treatment of Advanced Breast CancerStatus unknownNCT04683445Report a problem
• PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter StudyStatus unknownNCT04644406Report a problem
• Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer PatientsCompletedNCT04638712Not applicableReport a problem
• Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBCStatus unknownNCT04609540Report a problem
• An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicApproved for marketingNCT04395508Report a problem
• A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted TherapiesStatus unknownNCT04288141Report a problem
• Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP ChemotherapyStatus unknownNCT04276337Report a problem
• Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast CancerCompletedNCT04249440Report a problem
• Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved for marketingNCT04220203Report a problem
• A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompletedNCT04158258Report a problem
• Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBCCompletedNCT04001634Report a problem
• Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast CancerStatus unknownNCT03979911Report a problem
• Breast Cancer Treatment Based on Organ-like CultureStatus unknownNCT03925233Report a problem
• Real World Study of Lapatinib Among Metastatic Breast Cancer PatientsCompletedNCT03894410Report a problem
• Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast CancerActive, not recruitingNCT03892655Report a problem
• Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 TherapyTerminatedNCT03738553Report a problem
• Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast CancerStatus unknownNCT03728829Report a problem
• The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.TerminatedNCT03619044Not applicableReport a problem
• Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast CancerStatus unknownNCT03521245Report a problem
• Prognostic and Predictive Factors for Small Breast TumorsCompletedNCT03390608Report a problem
• CARdiac Function Evaluation in Breast Cancer PatientsCompletedNCT03266809Report a problem
• Investigating Cardiovascular Adverse Events Related to Cancer TreatmentActive, not recruitingNCT03199300Report a problem
• Trastuzumab Based Therapy in HER2 Positive AGCCompletedNCT03024450Report a problem
• Psychometric Validation (Quality-of-life Scale) in Young Women With a Non Metastatic Breast Cancer and Her PartnerCompletedNCT02858063Report a problem
• Monoclonal Antibodies Elimination in Breast Cancer PatientCompletedNCT02855775Not applicableReport a problem
• microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With HerceptinStatus unknownNCT02656589Report a problem
• Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer PatientsStatus unknownNCT02642458Report a problem
• Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer SurvivorsCompletedNCT02615054Report a problem
• A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast CancerCompletedNCT02443467Report a problem
• Safety of Herceptin/Trastuzumab in Metastatic Breast CancerCompletedNCT02424682Report a problem

← Trastuzumab